Integrating Innate Immunity into a Global “Systems” Context: The Complement Paradigm Shift - Systems Biology: Networks, Models, and Applications - page 185

10. Moore, M. D., R. G. DiScipio, N. R. Cooper, et al. Hydrodynamic, electron

microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg
receptor (CR2). Journal of Biological Chemistry , 264(34):20576-82, 1989.

11. Diefenbach, R. J. and D. E. Isenman. Mutation of residues in the C3dg

region of human complement component C3 corresponding to a proposed
binding site for complement receptor type 2 (CR2, CD21) does not abolish
binding of iC3b or C3dg to CR2. Journal of Immunology , 154(5):2303-20,
1995.

12. Clemenza, L. and D. E. Isenman. Structure-guided identification of C3d

residues essential for its binding to complement receptor 2 (CD21). Journal
of Immunology, 165(7):3839-48, 2000.

13. Guthridge, J. M., J. K. Rakstang, K. A. Young, et al. Structural studies in

solution of the recombinant N-terminal pair of short consensus/complement
repeat domains of complement receptor type 2 (CR2/CD21) and inter-
actions with its ligand C3dg. Biochemistry , 40(20):5931-41, 2001.

14. Sarrias, M. R., S. Franchini, G. Canziani, et al. Kinetic analysis of the interac-

tions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and
the EBV glycoprotein gp350/220. Journal of Immunology , 167(3):1490-9, 2001.

15. Morikis, D. and J. D. Lambris. The electrostatic nature of C3d-complement

receptor 2 association. Journal of Immunology , 172(12):7537-47, 2004.

16. Sfyroera, G., M. Katragadda, D. Morikis, et al. Electrostatic modeling

predicts the activities of orthopoxvirus complement control proteins.
Journal of Immunology , 174(4):2143-51, 2005.

17. Rosengard, A. M., Y. Liu, Z. Nie, et al. Variola virus immune evasion

design: expression of a highly efficient inhibitor of human complement.
Proceedings of the National Academy of Sciences USA , 99(13):8808-13, 2002.

18. Smith, D. L., Y. Z. Deng and Z. Q. Zhang. Probing the non-covalent struc-

ture of proteins by amide hydrogen exchange and mass spectrometry.
Journal of Mass Spectrometry, 32(2):135-46, 1997.

19. Mandell, J. G., A. M. Falick and E. A. Komives. Identification of

protein-protein interfaces by decreased amide proton solvent accessibility.
Proceedings of the National Academy of Sciences USA , 95(25):14705-10, 1998.

20. Mandell, J. G., A. M. Falick and E. A. Komives. Measurement of amide

hydrogen exchange by MALDI-TOF mass spectrometry. Analytical
Chemistry , 70(19):3987-95, 1998.

21. Winters, M. S., D. S. Spellman and J. D. Lambris. Solvent accessibility of

native and hydrolyzed human complement protein 3 analyzed by hydro-
gen/deuterium exchange and mass spectrometry. Journal of Immunology ,
174(6):3469-74, 2005.

22. Sahu, A. and J. D. Lambris. Complement inhibitors: a resurgent concept in

anti-inflammatory therapeutics. Immunopharmacology , 49:133-48, 2000.

23. Sahu, A. and J. D. Lambris. Structure and biology of complement protein

C3, a connecting link between innate and acquired immunity.
Immunological Reviews , 180:35-48, 2001.

24. Sahu, A. and J. D. Lambris. Complement inhibitors: a resurgent concept in

anti-inflammatory therapeutics. Immunopharmacology , 49:133-48, 2000.

25. Sahu, A., B. K. Kay and J. D. Lambris. Inhibition of human complement by

a C3-binding peptide isolated from a phage displayed random peptide
library. Journal of Immunology , 157(2):884-91, 1996.